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Abstract (175 words) 
The mitochondrial pyruvate carrier (MPC) is critical for cellular homeostasis, as it is 
required in central metabolism for transporting pyruvate from the cytosol into the 
mitochondrial matrix. MPC has been implicated in many diseases and is being 
investigated as a drug target. A few years ago, small membrane proteins, called 
MPC1 and MPC2 in mammals and Mpc1, Mpc2 and Mpc3 in yeast, were proposed 
to form large protein complexes responsible for this function. However, the MPC 
complexes have never been isolated and their composition, oligomeric state and 
functional properties have not been defined. Here, we identify the functional unit of 
MPC from Saccharomyces cerevisiae. In contrast to earlier hypotheses, we 
demonstrate that MPC is a hetero-dimer, not a multimeric complex. When not 
engaged in hetero-dimers, the yeast Mpc proteins can also form homo-dimers that 
are, however, inactive. We show that the earlier described substrate transport 
properties and inhibitor profiles are embodied by the hetero-dimer. This work 
provides a foundation for elucidating the structure of the functional complex and 
the mechanism of substrate transport and inhibition. 
 






In recent years, there is an increasing understanding and appreciation that 
mitochondrial metabolism is involved in major human diseases, such as cancer, 
neurodegeneration, cardiovascular diseases, metabolic disorders, obesity and 
diabetes. A key player for the metabolic fate of the cell is the mitochondrial pyruvate 
carrier (MPC), a protein responsible for the uptake of pyruvate from the cytosol into 
the mitochondrial matrix (Vanderperre et al., 2015), where it enters the tricarboxylic 
acid cycle and other biosynthetic pathways. The existence of a membrane protein 
responsible for pyruvate transport across the mitochondrial inner membrane had 
been supported by early work on isolated mitochondria, where pyruvate transport 
had been shown to be saturating and pH-dependent (Papa et al., 1971, Papa & 
Paradies, 1974). In addition, small molecule inhibitors had been identified in support 
of this notion (Halestrap, 1975, Halestrap, 1976, Halestrap & Denton, 1974), but the 
molecular identity of the protein remained unknown for four decades. 
Major progress was made in 2012, when mitochondrial pyruvate transport 
activity was discovered to be associated with two small homologous proteins, MPC1 
and MPC2 (Bricker et al., 2012, Herzig et al., 2012). In mammals and drosophila the 
expression of both MPC proteins is necessary for pyruvate transport (Bricker et al., 
2012, Herzig et al., 2012). In yeast Saccharomyces cerevisiae, three proteins Mpc1, 
Mpc2 and Mpc3 are expressed in a carbon source-dependent pattern, forming an 
Mpc1/Mpc2 complex under fermentative conditions and an Mpc1/Mpc3 under 
respiratory conditions, called MPCFERM and MPCOX complexes, respectively (Bender 
et al., 2015, Compan et al., 2015).   
As the mitochondrial pyruvate carrier is central for cellular homeostasis, the 
identification of the MPC proteins intensified efforts to understand their role in cancer 
(Bader et al., 2019, Corbet et al., 2018, Li et al., 2017, Li et al., 2016, Ohashi et al., 
2018, Schell et al., 2014, Schell et al., 2017, Yang et al., 2014, Zhong et al., 2015), 
diabetes (Colca et al., 2013, Divakaruni et al., 2013, Gray et al., 2015, McCommis et 
al., 2015, McCommis et al., 2016, Vadvalkar et al., 2017, Vigueira et al., 2014) and 
neurodegeneration (Divakaruni et al., 2017, Ghosh et al., 2016, Quansah et al., 
2018). Moreover, pathogenic mutations in the mpc1 gene were found in rare but 
severe metabolic syndromes, further enhancing the clinical relevance of this 
transporter (Bricker et al., 2012). Additionally, an increasing number of small-
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molecule drugs, previously known to have other targets, have now been proposed to 
inhibit MPC activity (Chen et al., 2018, Colca et al., 2013, Corbet et al., 2018, 
Divakaruni et al., 2013, Du et al., 2013, Ghosh et al., 2016, Nancolas et al., 2016, 
Nath et al., 2016). MPC is a newly identified target for the first generation insulin 
sensitisers, called thiazolidinediones (TZDs) (Colca et al., 2013, Divakaruni et al., 
2013), originally known to exert their action on the peroxisome proliferator-activated 
receptor gamma (PPARγ) (Nanjan et al., 2018, Soccio et al., 2014). More recently, a 
new generation TZD, bypassing PPARγ (Colca et al., 2014) and currently in clinical 
trials for the treatment of Parkinson’s disease, was proposed to exert its action by 
inhibiting MPC (Ghosh et al., 2016). Despite these major advances, a direct 
experimental system to measure the interactions of small-molecule drugs with MPC 
and to study the mechanism of inhibition is not available. 
Six years after the primary identification of the MPC proteins (Bricker et al., 
2012, Herzig et al., 2012), there has been no report of a successful purification and 
functional reconstitution of an MPC hetero-complex. Consequently, the composition 
of the MPC complexes, the oligomeric state and the protomer stoichiometry remain 
controversial (Bender et al., 2015, Bricker et al., 2012, Nagampalli et al., 2018) and 
their involvement in pyruvate transport has been questioned (Halestrap, 2012). The 
yeast MPC hetero-complexes migrate at 150 kDa (Bender et al., 2015, Bricker et al., 
2012) or at even higher molecular weights (Bender et al., 2015) in blue native gel 
electrophoresis, leading to proposals that the complexes are multimeric and might 
even include additional, yet unidentified proteins (Bricker et al., 2012, Halestrap, 
2012). The application of chemical cross-linking on MPC proteins has produced 
bands corresponding to monomers, dimers as well as higher oligomers (Bender et 
al., 2015, Nagampalli et al., 2018). In the only published attempt to purify an MPC 
hetero-complex, it was only possible to purify individual MPC protomers (Nagampalli 
et al., 2018). It has also been proposed that the individual human MPC2 protein can 
form high-order multi-species capable of transporting pyruvate (Nagampalli et al., 
2018), raising more questions regarding the functional unit of the mitochondrial 
pyruvate carrier.  
Here, we report the first successful purification and characterisation of MPC 
hetero-complexes from yeast, providing a model system for future structural and 
mechanistic studies. We demonstrate that the natural state of yeast MPC is a hetero-
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dimer capable of transporting pyruvate. In the absence of other protomers, MPC 
proteins can form homo-dimers, but they do not transport pyruvate. 
 
Results 
Expression and purification of the yeast Mpc proteins 
Although it has been established that the MPC proteins constitute the mitochondrial 
pyruvate carrier (Bricker et al., 2012, Herzig et al., 2012), there are still many 
outstanding questions regarding the composition and the oligomeric state of the 
functional complex. The most straightforward way to settle these issues is through 
the purification and reconstitution of the individual components and putative 
complexes to determine whether they have pyruvate transport activity.  
 Here, we have used the Mpc proteins from S. cerevisiae (Fig EV1) as a model 
system to study the composition and functional properties of the mitochondrial 
pyruvate carrier. We decided to concentrate on the Mpc1/Mpc3 complex, as it is the 
principle pyruvate carrier in oxidative phosphorylation (MPCOX) (Bender et al., 2015). 
It is also the most related to MPCs of mammals and other organisms, whereas the 
Mpc1/Mpc2 complex (MPCFERM), expressed under fermentative conditions, only 
exists in some fungi. The principal approach was to purify the Mpc1/Mpc3 hetero-
complex by tagging one of the two protomers with a Factor Xa cleavage site and an 
eight-histidine tag on the C-terminus (Fig 1A). To achieve co-expression of the 
protein pair we used an inducible bi-directional vector (Miller et al., 1998) for 
expression in mitochondria of the mpc triple deletion strain SHY15 (Herzig et al., 
2012). We also expressed the C-terminally tagged Mpc1 and Mpc3 proteins 
individually in yeast mitochondria. 
All proteins expressed well, both in the presence and the absence of their 
proposed complex partner (Fig 1B). It is notable though that in expression trials of 
Mpc1 alone an additional prominent band appeared, approximately corresponding to 
the molecular weight of an SDS-resistant dimer, as detected by immunoblotting of 
crude yeast mitochondrial preparations (Fig 1B, left panel). However, this band was 
not detected in mitochondria expressing the untagged Mpc1 protein (Fig 1B, left 
panel). For these reasons, we chose to co-express an unmodified Mpc1 together with 
a tagged Mpc3 for hetero-complex formation.  
With this strategy, the purification of the Mpc1/Mpc3 hetero-complex was 
successful and both proteins were present in a 1:1 ratio (Fig 1C). The highest protein 
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yield (~1 mg protein per g of mitochondria) was achieved with the detergent lauryl 
maltose neopentyl glycol (LMNG), supplemented with tetraoleoyl cardiolipin. 
However, the stoichiometric Mpc1/Mpc3 complex could also be purified in Triton X-
100, decyl maltose neopentyl glycol (DMNG) or n-dodecyl β-D-maltoside (DDM), 
each supplemented with tetraoleoyl cardiolipin, albeit with lower purification yields 
(Fig EV2). In LMNG and tetraoleoyl cardiolipin, the Mpc1/Mpc3 complex eluted as a 
single peak by size-exclusion chromatography, indicating that the complex was 
monodisperse (Fig EV3). Moreover, analysis of the peak fractions showed that the 
protomers remained associated during purification, consistent with a stable complex 
(Fig EV3, A, inset). When we purified histidine-tagged Mpc1 or Mpc3 on their own in 
LMNG and tetraoleoyl cardiolipin (Fig 1C), the yields were at least three times lower, 
despite similar expression levels in mitochondria in the presence or absence of their 
partner (Fig 1B), indicating stability issues. After purification and histidine-tag 
cleavage, Mpc1 contained again an SDS-resistant dimer (Fig 1C), as detected by 
peptide mass fingerprinting (Table EV1). 
Next, we used thermostability analysis to evaluate folding and stability of the 
hetero-complex and its components. For this purpose, we monitored the unfolding of 
protein populations in a temperature ramp in the presence of 7-diethylamino-3-(4-
maleimidophenyl)-4-methylcoumarin (CPM), which reacts with cysteine residues 
becoming exposed due to denaturation (Fig 1D). Mpc1 and Mpc3 both have a single 
cysteine residue (Fig EV1). The Mpc1/Mpc3 hetero-complex and the individual Mpc3 
protein had very similar unfolding profiles and melting temperatures (52.0 and 51.7 
°C respectively), clearly showing that they are folded and stable in detergent solution. 
The Mpc1 protein on its own, however, did not display a thermal denaturation profile 
and high fluorescence was detected throughout the temperature ramp. This result 
means that either Mpc1 is unfolded or its single cysteine is already exposed. To 
discriminate between these two possibilities, we also performed thermostability 
analysis by nano differential scanning fluorimetry (nanoDSF) (Fig 1E), which relies on 
changes in the environment of endogenous tyrosine and tryptophan residues. Again, 
the hetero-complex and Mpc3 had similar apparent melting temperatures, 48.5 and 
48.0 °C, respectively, similar to those obtained with CPM. However, Mpc1 alone 
showed a peak at 64.5 °C, which might correspond to the SDS-resistant dimer, 
possibly being an aggregation artefact.  
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The ability of Mpc proteins to form hetero-complexes was also demonstrated 
when we expressed and purified the Mpc1/Mpc2 (MPCFERM) hetero-complex (Bender 
et al., 2015) using a histidine tag on Mpc2 (Fig EV4, A and B). We also compared the 
Mpc1/Mpc2 hetero-complex to the histidine-tagged Mpc2, expressed and purified 
alone (Fig EV4). Although Mpc2 can be expressed in mitochondria equally well on its 
own or together with Mpc1 (Fig EV4, A), it could not be purified alone in sufficient 
quantities and could only be detected by peptide mass fingerprinting (Fig EV4, B and 
Table EV1). Interestingly though, when they were expressed together, Mpc2 with 
Mpc1 successfully formed a hetero-complex, which was purified and had an apparent 
melting temperature of 42 °C (Fig EV4, C).  
This is the first purification of MPC hetero-complexes, demonstrating that 
different Mpc protomers can form stable interactions. Of the two hetero-complexes, 
the principal complex Mpc1/Mpc3 was purified at higher yields, was 10°C more 
thermostable and was, therefore, selected for characterisation of its oligomeric 
state. 
 
The Mpc1/Mpc3 hetero-complex is a dimer. 
We showed that the protomers are present in a 1:1 molar ratio in the hetero-
complexes (Fig 1C), but this does not resolve the issue of the overall mass of the 
complex. Previous work on the yeast Mpc proposed that the protein is a multimeric 
complex of 150 kDa, based on its electrophoretic mobility by blue native gel 
electrophoresis (Bricker et al., 2012) and this notion has been largely accepted in the 
literature. However, the electrophoretic mobility on blue native gels depends on the 
associated detergent and lipids present during protein extraction, as both the 
detergent-lipid micelle (DL) and the protein bind Coomassie stain, leading to 
anomalous migration (Crichton et al., 2013). Therefore, blue native gel 
electrophoresis is not an appropriate technique for sizing of small membrane 
proteins. Another approach that has been used involves chemical cross-linking with 7 
and 15 Å long cross-linkers. The cross-linked MPC proteins appeared on SDS-PAGE 
in multiple bands corresponding to monomers, dimers and different higher oligomers 
(Bender et al., 2015, Nagampalli et al., 2018), but it cannot be excluded that the 
detected states are the result of non-specific cross-linking events. 
Here, we determined the molecular mass, oligomeric state and subunit 
stoichiometry of the affinity-purified Mpc1/Mpc3 hetero-complex by using size-
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exclusion chromatography linked to multi-angle laser light scattering (SEC-MALLS) 
(Figs 2A and B). This technique can determine the mass of the protein-detergent-lipid 
complex (PDL) and of the protein itself (Slotboom et al., 2008, ter Beek et al., 2011). 
The analysis showed that on average the mass of the Mpc1/Mpc3 hetero-complex is 
contributing 30.8 ± 1.4 kDa to a 163.3 ± 5.1 kDa protein-detergent-lipid complex 
(Table EV2 and Fig 2B). The protein mass corresponded well to the sum of the 
theoretical masses of Mpc1 (15 kDa) and Mpc3 (17.1 kDa), which demonstrates that 
the complex is a hetero-dimer. Similar results were obtained whether the protein was 
purified by a single affinity chromatography step or by an additional size-exclusion 
chromatography step (Table EV2). 
To exclude other possible stoichiometries, we performed an internal 
consistency analysis (Wen et al., 1996), where theoretical molecular masses for the 
complex, corresponding to different possible subunit stoichiometries, were calculated 
and compared with the experimentally determined molecular mass. The analysis was 
only consistent with a Mpc1/Mpc3 hetero-dimeric complex, showing the smallest 
difference between the experimentally determined and theoretical molecular masses 
(Table 1). Additionally, since Mpc1 and Mpc3 co-purify in equimolar amounts and 
remain associated throughout the SEC-MALLS step (Fig 2B, inset), the possibility 
that the calculated mass corresponds to separate homo-dimers is eliminated.  
Since Mpc3 can be purified on its own (Figs 1C and EV3) and is stable in 
solution, it was also analysed by SEC-MALLS (Fig 2C and D). The average 
molecular mass for the protein-detergent-lipid complex was 182.9 ± 7.9 kDa with the 
protein contributing 34.8 ± 0.7 kDa (Table EV2 and Fig 2D), which is approximately 
twice the theoretical mass of Mpc3 (17.1 kDa). Thus, Mpc3 forms homo-dimers in the 
absence of Mpc1. 
 
The Mpc1/Mpc3 hetero-dimer is the active mitochondrial pyruvate carrier 
To investigate whether the Mpc1/Mpc3 hetero-dimer is capable of pyruvate transport, 
we established a reconstitution and transport protocol. We prepared proteoliposomes 
of the purified hetero-dimer loaded with 5 mM unlabelled pyruvate in buffer at pH 8.0 
(Fig 3) or 7.4 (Fig EV5) and we initiated pyruvate homo-exchange by addition of 
radiolabelled pyruvate (50 μM) on the outside. To evaluate the pH dependence of 
transport, we performed our assays with external buffer at different pH units (Fig 3 
and EV5).  
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In proteoliposomes loaded with internal buffer at pH of 7.4 (Fig EV5) we 
observed that diffusion, as determined by [14C]-pyruvate accumulation in empty 
liposomes, was pH-dependent and highest in acidic pH of 5.4, when pyruvate 
accumulation into empty liposomes reached levels even higher than into 
proteoliposomes. This result is consistent with previous studies suggesting that 
pyruvate can cross the mitochondrial membrane via “absorption”, depending on its 
protonation state (Bakker & van Dam, 1974, Klingenberg, 1970, Zahlten et al., 1972). 
Therefore, the selection of internal and external pH units is critical. Our finalised 
pyruvate transport protocol (Fig 3) was based on achieving the maximal ΔpH under 
conditions where the diffusion is minimal. 
When we selected an internal pH of 8.0 and external pH of 6.4, yielding a ΔpH 
of 1.6, high pyruvate homo-exchange activity was observed (Fig 3A) with an initial 
uptake rate of 1.6 ± 0.2 µmol/min/mg protein, demonstrating that the purified 
Mpc1/Mpc3 hetero-dimer is capable of transporting pyruvate. This homo-exchange 
reaction was completed within seconds when performed at room temperature. Under 
these conditions, the maximum transport rate (Vmax) was 8 ± 3 µmol/min/mg protein 
and the apparent KM of transport for pyruvate was 342 ± 58 µM (Fig 3B). We were 
also able to measure homo-exchange activity at a ΔpH of 0.8 (internal pH of 8.0, 
external pH of 7.2), which is physiologically relevant to mitochondria, albeit with lower 
signal (Fig 3C). The activity was abolished in the absence of a ΔpH (Fig 3D), 
showing that transport is pH-dependent, as previously proposed for the carrier in 
mitochondria (Papa et al., 1971, Papa & Paradies, 1974). Importantly, the 
Mpc1/Mpc2 hetero-complex was also active for ΔpH-dependent pyruvate transport 
(Figure EV4, D). 
It is expected that transport by a functional MPC should be inhibited by 
UK5099, a well-established inhibitor of pyruvate transport in rat, mouse or human 
mitochondria (Halestrap, 1975). We tested whether UK5099 can also inhibit pyruvate 
homo-exchange by the yeast Mpc1/Mpc3 hetero-dimer. Indeed, in the presence of 
UK5099 the initial rates of transport were inhibited, with the IC50 being at the low 
micromolar range (9 ± 7 μM from three biological repeats and Fig 3E). This is a 
greater value than reported for mammalian MPC proteins, where the IC50 for UK5099 
is in the nanomolar range, probably reflecting differences in inhibitor binding between 
yeast and mammalian complexes. We also tested Zaprinast, a phosphodiesterase 
inhibitor, which was reported to block pyruvate oxidation and pyruvate influx in 
 10 
mouse mitochondria (Du et al., 2013), and 7ACC2, a carboxycoumarin inhibitor of the 
monocarboxylate transporter 1 (MCT1), also proposed to inhibit MPC. The inhibition 
of pyruvate exchange was similar for Zaprinast and 7ACC2 with an average IC50 of 
18 ± 8 μM and 27 ± 13 μM, respectively. Lonidamine, an anti-tumour agent proposed 
to inhibit the monocarboxylate transporters (MCTs) as well as MPC, inhibited the 
yeast hetero-complex but with a higher IC50 of 118 ± 24 μM. Finally, we tested two 
thiazolidinediones (Fig 3F). Unlike the other tested compounds, pioglitazone had no 
effect on pyruvate transport by Mpc1/Mpc3. Rosiglitazone inhibited pyruvate 
transport to 52 ± 7 % but at a high concentration (500 μM) suggesting that some 
TZDs might be inhibiting the yeast complex, albeit with very low affinity.  Taken 
together, our work shows that the reconstituted Mpc1/Mpc3 hetero-dimer displays the 
expected characteristics of the mitochondrial pyruvate carrier, providing the first 
direct experimental evidence of the functional unit.  
 
Individual MPC proteins form homo-dimers but they are not functional 
In the absence of other Mpc proteins, Mpc3 formed a stable homo-dimer (Fig 2C and 
D). The human MPC2 protein, which is related to Mpc3, was recently purified and 
reconstituted into liposomes and was proposed to have pyruvate transport activity 
(Nagampalli et al., 2018). To clarify whether the individual yeast Mpc proteins are 
capable of pyruvate transport, under conditions where their partner is not expressed, 
we purified and reconstituted Mpc1 and Mpc3 separately in liposomes and tested 
whether they could transport pyruvate. In parallel, the Mpc1/Mpc3 hetero-complex 
was used as control. While the hetero-complex mediated robust pyruvate homo-
exchange at a ΔpH of 1.6, there was no measurable activity for Mpc3 or Mpc1 alone 
(Fig 4A and 4B). It is unlikely that this result is due to differences in reconstitution. 
First, the purified Mpc3 homo-dimer is as stable in detergent as the functional hetero-
dimer (Fig 1D and E) and second a similar amount of Mpc3 was reconstituted into 
liposomes as the Mpc1/Mpc3 complex. 
We were able to extend our analysis and compared the properties of the 
Mpc1/Mpc3 hetero-dimer with the Mpc3 homo-dimer, taking advantage of the CPM 
thermostability assay, where both proteins showed similar unfolding profiles (Fig 1D). 
It has been previously shown that binding events, creating new interactions between 
membrane proteins and inhibitors, result in an increased apparent melting 
temperature in thermostability analyses (Alexandrov et al., 2008, Crichton et al., 
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2015). If inhibitors bind to MPC, their interaction with the protein should also lead to a 
shift in thermostability upon binding. Indeed, at saturating concentrations, Zaprinast 
stabilised the Mpc1/Mpc3 hetero-complex by shifting the apparent melting 
temperature from 53.7 to 57 °C (Fig 4C), consistent with its ability to inhibit transport. 
However, Zaprinast did not have an effect on the thermostability of the Mpc3 homo-
dimer (Fig 4C), consistent with the inhibitor not interacting with Mpc3 alone. 
Unfortunately, we were not able to include UK5099 in this analysis as this coloured 
compound quenches the fluorescent signal, complicating interpretation. Since Mpc1 
did not show an unfolding curve in the CPM analysis (Fig 1D), we tested the effect of 
Zaprinast on Mpc1 via nanoDSF, using Mpc1/Mpc3 as a control (Fig 4D). While the 
Mpc1/Mpc3 hetero-complex was stabilized by Zaprinast, no stabilizing shift was 
observed for Mpc1, but it is possible that the protein is not in a competent state. 
Overall, our results show that Mpc protomers can form homo-dimers, but they do not 
transport pyruvate and do not bind the inhibitor Zaprinast. 
 
Discussion 
Despite the fundamental role of MPC in metabolism and disease, little was known 
about its composition and mechanism of transport and inhibition. We present here 
robust evidence that the mitochondrial pyruvate carrier is functional as a hetero-
dimer. When the Mpc protomers from S. cerevisiae were expressed, purified and 
reconstituted into liposomes in combinations, the hetero-dimeric complexes were 
functional, whereas the individual proteins formed inactive homo-dimers.  
Our results on the yeast Mpc are different than the published results on the 
human MPC proteins, where a co-expression and co-purification strategy did not lead 
to hetero-complex formation (Nagampalli et al., 2018). Specifically, in the presence of 
the co-expressed MPC1, the MPC2 protein was purified alone. This is not consistent 
with genetic and functional analyses of mammalian MPCs, including the human 
MPC, where co-expression of both MPC proteins was found to be necessary for 
mitochondrial pyruvate carrier activity (Bricker et al., 2012, Compan et al., 2015, 
Herzig et al., 2012, Vanderperre et al., 2016). We show here that the co-expressed 
yeast Mpc proteins co-purify to form folded and stable hetero-dimers in detergent 
solution. It is not possible to safely conclude on the oligomeric state of the 
mammalian MPCs, as it could differ between species, but our strategy can be applied 
to characterise the mammalian MPC complexes. 
 12 
Establishing the oligomeric state of MPC is a first step to understand its 
bioenergetics and transport mechanism. Our results directly contradict the idea that 
the MPC proteins form multimeric complexes of 150 kDa, as proposed previously 
based on blue native gel electrophoretic analysis of the yeast complex Mpc1/Mpc2 
(Bricker et al., 2012). We have shown here that within a large protein-detergent-lipid 
complex (163.3 ± 5.7 kDa in our experimental setup), the protein contribution was 
only 30.8 ± 1.3 kDa, clearly corresponding to a hetero-dimer.  It is likely that the 
anomalous migration of MPC on blue native gels is caused by binding of Coomassie 
stain to both the protein and the detergent-lipid micelle, as observed for other small 
membrane proteins (Crichton et al., 2013). 
We also provide here strong evidence for the ability of the MPC hetero-dimers 
to transport pyruvate by measuring pyruvate homo-exchange activity, which was 
inhibited by previously proposed MPC inhibitors, such as UK5099, Zaprinast, 
lonidamine, 7ACC2 and the TZD rosiglitazone. Pyruvate exchange was dependent 
on the ΔpH and the measured apparent affinity for pyruvate (KM) was in line with 
other studies of pyruvate transport (Gray et al., 2016, Halestrap, 1975) and pyruvate 
homo-exchange in isolated mitochondria (Papa & Paradies, 1974, Paradies & Papa, 
1975). These results demonstrate that the hetero-dimer is the functional unit of the 
yeast mitochondrial pyruvate carrier. Our experimental system provides now a 
unique opportunity to study the detailed mechanism of pyruvate transport by the 
MPC hetero-complexes in yeast but also creates new opportunities for the 
purification and reconstitution of the human MPC hetero-complex. 
Consistent with previous observations that some MPC proteins homo-
oligomerise (Bender et al., 2015, Bricker et al., 2012, Nagampalli et al., 2018) we 
found that Mpc1 and Mpc3 can be expressed and purified individually and we 
showed that Mpc3 forms stable homo-dimers, but only when it is expressed 
individually. Under normal conditions, it engages in hetero-complex formation with 
Mpc1. In our system, no transport activity could be detected for Mpc1 or Mpc3 homo-
dimers in conditions where the hetero-dimer showed robust transport activity. The 
reason might be that pyruvate is an asymmetric substrate, requiring an asymmetric 
binding pocket for co-ordination, which cannot be provided by a homo-dimer. 
Additionally, unlike the Mpc1/Mpc3 hetero-complex, the Mpc3 or Mpc1 alone did not 
interact with Zaprinast. Therefore, the yeast Mpc homo-dimers are not functional and 
they may not form a functional binding pocket.  
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Mpc1, Mpc2 and Mpc3 are highly homologous membrane proteins throughout 
the length of the conserved parts, strongly suggesting that the topology of all three 
must be very similar (Fig EV1). The observation that Mpc3 can form both a functional 
hetero-dimer with Mpc1 and non-functional homo-dimer also indicates that these 
proteins must have similar structures. Investigation of the secondary structure and 
hydropathy profile indicates that the yeast Mpc proteins may have three 
transmembrane D-helices each (Fig EV1). The N-terminal region also has the 
propensity to form an D-helix, which is amphipathic in nature, whereas the secondary 
structure of the C-terminal region, which is highly variable in length, is unclear. The 
distantly related semi-SWEET transporters, which import sugars into bacteria (Lee et 
al., 2015, Xu et al., 2014), have a similar topology and also dimerise. 
This work provides the basis for understanding the function of the MPC 
hetero-complex, the detailed mechanism of substrate transport and inhibition and the 
substrate specificity profile. Moreover, it will pave the way towards structural analysis 
of the complex. These studies will be important in light of the central role of MPC in 
metabolism, its involvement in diseases and its potential use as a drug target. 
 
Materials and methods 
Molecular biology  
The codon-optimised gene sequences for Mpc1 (UniProt: P53157), Mpc2 (UniProt: 
P38852) and Mpc3 (UniProt: P53311) from S. cerevisiae were synthesised 
(GenScript) and cloned into the bidirectional expression vector pBEVY-GU (gift 
from Charles Miller; Addgene plasmid # 51229 (Miller et al., 1998)). For expression 
of mpc1, the cDNA was subcloned into the EcoRI/SacI sites and for mpc2 or mpc3 
into the BamHI/XbaI sites. Where indicated, the sequences were designed to 
include a sequence coding for Factor Xa cleavage site (IEGR), followed by an 
octa-histidine tag at their C-termini. For expression of individual proteins, each 
single sequence was subcloned in the EcoRI/SacI sites of the same vector. 
 
Protein expression and mitochondrial preparations. 
The expression plasmids were transformed into an mpc triple deletion strain of S. 
cerevisiae (SHY15) (Herzig et al., 2012) or into the W303-1B strain (MATα leu2-3, 
112 trp1-1 can1-100 ura3-1 ade2-1 his3-11,15), using standard methods (Gietz & 
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Schiestl, 2007). Successful transformants were selected on synthetic-complete 
uracil-dropout medium (Formedium) plates supplemented with 2 % (w/v) glucose. 
Pre-cultures were grown in the same medium and used to inoculate 50 L of YPG 
medium containing 0.1 % (w/v) glucose in an Applikon Pilot Plant 140-L bioreactor 
(Thangaratnarajah et al., 2014). Protein expression was induced for 3 h with 0.4 % 
(w/v) galactose, after 20 h of growth in YPG. Mitochondrial isolation was performed, 
as previously described (Thangaratnarajah et al., 2014), using a DYNO-MILL (Willy 
A. Bachofen). Isolated mitochondria were aliquoted, flash-frozen in liquid nitrogen 
and stored in -80 °C until use.  
 
Affinity chromatography  
All the protomers (Mpc1, Mpc2, Mpc3) and the Mpc1/Mpc2 hetero-complex were 
expressed in and purified from mitochondria of the SHY15 strain. The Mpc1/Mpc3 
hetero-complex was expressed in both SHY15 and W303-1B strains, and yielded the 
same results with respect to the Mpc1/Mpc3 protein ratio and stability. The W303-1B 
strain was selected for large-scale purification of Mpc1/Mpc3 based on the total 
protein yield. Immediately prior to purification, 1 g of mitochondria were thawed and 
suspended in buffer containing 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 % (v/v) 
glycerol, one Complete EDTA-free protease inhibitor cocktail tablet (Roche) and 1 % 
(w/v) lauryl maltose neopentyl glycol (LMNG, Anatrace). Mitochondria were 
solubilised for 1.5 h at 4 °C under gentle agitation, and then clarified by 
ultracentrifugation at 205,000 x g for 45 min. The supernatant was incubated for 2 h 
with nickel Sepharose beads (GE Healthcare), previously equilibrated with 20 mM 
Tris-HCl, pH 7.4, 150 mM NaCl, and then poured into an empty column (Bio-Rad). 
The column was initially washed with 20 column volumes of Buffer A (20 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 40 mM imidazole, 0.1 % (w/v) LMNG, 0.1 mg/ml 
tetraoleoyl cardiolipin (TOCL)), followed by 20 column volumes of buffer B (20 mM 
Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM CaCl2, 0.1 % (w/v) LMNG, 0.1 mg/ml 
TOCL). Mpc1/Mpc3 was eluted from the column by on-column digestion for 12 h at 
4 °C with 10 μg of Factor Xa protease (New England Biolabs) per 1 g of 
mitochondria. Mpc1/Mpc2 was eluted after 1 h cleavage with Factor Xa with 10 μg 
of Factor Xa per 1 g of mitochondria. The mobile phase containing untagged MPC 
was separated from the resin with empty Proteus Midi spin columns (Generon) at 
200 x g for 5 min. Protein concentration was determined by the bicinchoninic acid 
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assay (Thermo Fisher Scientific). Freshly purified protein was used for 
reconstitution into liposomes and for size-exclusion chromatography (SEC) coupled 
to multi-angle laser light scattering (MALLS), called SEC-MALLS.  
 
Size-exclusion chromatography 
Analytical size-exclusion chromatography was performed on an ÄKTA Explorer (GE 
Healthcare) with a Superdex 200 10/300 GL column (GE Healthcare) equilibrated in 
SEC buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.05 % (w/v) LMNG, 0.05 mg/ml 
TOCL). Nickel purified proteins were injected without being concentrated onto the 
column at 0.3 ml/min and 0.15 ml fractions were collected. The column was 
calibrated with a high molecular weight calibration kit (GE Healthcare) in the same 
buffer without detergent and lipid.  
 
Thermostability analysis using a thiol reactive probe 
The assessment of protein stability was performed via thermal denaturation using a 
rotary quantitative PCR (qPCR) instrument as previously described (Crichton et al., 
2015). In this method, cysteine residues, buried within the protein structure, become 
solvent exposed during denaturation in a temperature ramp and react with N-[4-(7-
diethylamino-4-methyl-3-coumarinyl)phenyl]-maleimide (CPM) to form fluorescent-
adducts. Briefly, a CPM working solution was prepared by diluting the CPM stock (5 
mg/ml in dimethyl sulfoxide) 50-fold into assay solution (20 mM Tris-HCl, pH 7.4, 
150 mM NaCl, 5 mM CaCl2, 0.1 % (w/v) LMNG, 0.1 mg/ml TOCL), and incubated for 
10 min at room temperature. For each analysis, carried out in triplicates, 3 μg of 
purified MPC were diluted into the same buffer to a final volume of 45 μl, to which 5 
μl of the CPM working solution were added. When testing the effect of MPC inhibitors 
by thermostability shift assays, the protein was diluted in assay buffer containing the 
desired concentration of the inhibitor and then 5 μl of the CPM working solution were 
added. In each case, samples were incubated on ice for a further 10 min and then 
subjected to a temperature gradient from 25 to 90 °C at 1 °C increments with a 4 s 
hold, corresponding to a temperature ramp of 5.6 °C/min. The fluorescence increase 
was monitored with the HRM channel of the machine (excitation at 440–480 nm, 
emission at 505–515 nm). Unfolding profiles were analysed with the Rotor-Gene Q 
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software 2.3 and the peaks of their derivatives were used to determine the apparent 
melting temperature as a relative measure of protein stability. 
 
Thermostability analysis by nanoDSF 
The protein stability was also assessed using dye-free nano differential scanning 
fluorimetry (nanoDSF), which monitors fluorescence changes due to altered 
environments of tryptophan and tyrosine residues during unfolding. Protein samples 
in buffer containing 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM CaCl2, 0.1 % (w/v) 
LMNG, 0.1 mg/ml TOCL, in the presence or absence of the indicated 
concentrations of small molecule inhibitors, were loaded into capillary tubes, and 
subjected to a temperature gradient from 20 to 95 °C with a temperature ramp of 5 
°C/min. The intrinsic fluorescence was measured using the NanoTemper 
Prometheus NT.48 instrument.  
 
Immunoblotting 
Protein concentrations of crude mitochondrial preparations, isolated from the S. 
cerevisiae SHY15 (Herzig et al., 2012) or W303-1B strains, were determined by the 
bicinchoninic acid assay (Pierce). Twenty-five micrograms of mitochondria were 
subjected to SDS-PAGE (4-20 % gradient gel) and proteins were electroblotted onto 
polyvinylidene difluoride (PVDF) membranes. Proteins were probed with polyclonal 
antibodies raised in hen against Mpc peptides (Agrisera) and detected with a rabbit 
anti-chicken (IgG) horseradish peroxidase conjugate (Sigma, A9046). The antibodies 
were raised against a synthetic peptide corresponding to residues 111-126 of Mpc1 
and residues 40–54 of Mpc3. For detection of Mpc2, a mouse anti-his antibody 
(Roche, 04905318001) was used, followed by goat anti-mouse (IgG) horseradish 
peroxidase conjugate (Thermo Fisher Scientific, G21040). The signal was developed 
using the ECL reagent Western blot detection kit (GE Healthcare) and visualised on 
X-ray films. 
 
Mass determination by SEC-MALLS 
SEC-MALLS analysis was performed with a Superdex 200 10/300 GL column (GE 
Healthcare) on an ÄKTA Explorer (GE Healthcare) coupled in-line with a light 
scattering detector (Dawn HELEOSII, Wyatt Technologies) and a refractometer 
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(Optilab T-rREX, Wyatt Technologies). The Mpc1/Mpc3 complex or the individual 
Mpc3 protein were injected at 0.3 ml/min onto the Superdex 200 10/300 GL 
column equilibrated with 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.005 % (w/v) 
LMNG, 0.005 mg/ml TOCL. All data were recorded and analysed with ASTRA 6.03 
(Wyatt Technologies). Molecular weight calculations were performed using the 
protein-conjugate method (Slotboom et al., 2008) with the dn/dc value for protein 
of 0.185 ml/g and dn/dc value for LMNG-TOCL of 0.1675 ml/g (Thangaratnarajah 
et al., 2014). To determine the contribution of each protein to the overall protein-
detergent-lipid complex, the extinction coefficients εA280 were calculated from the 
amino-acid sequence using the ProtParam tool on the ExPaSy server (Gasteiger 
et al., 2005).  
Reconstitution in proteoliposomes 
Egg L-α-phosphatidylcholine 99 % (Avanti Polar Lipids) and tetraoleoyl cardiolipin 
(Avanti Polar Lipids) were mixed in a 20:1 (w/w) ratio, dried under a stream of 
nitrogen and washed once with methanol before being dried again. Lipids were 
hydrated in 20 mM Tris-HCl, pH 8.0, 50 mM NaCl to a concentration of 12 mg/ml. 
Cold pyruvate to be internalised was added as a freshly made concentrated stock, 
where indicated. Lipids were solubilised with 1.2 % (v/v) pentaethylene glycol 
monodecyl ether (Sigma) and freshly purified protein was added at a lipid-to-
protein ratio of 250:1 (w/w) for Mpc1/Mpc3 and 125:1 for Mpc1/Mpc2. Samples 
were incubated on ice for 5 min, after which liposomes were formed by the step-
wise removal of pentaethylene glycol monodecyl ether by five additions of 60 mg 
Bio-Beads SM-2 (Bio-Rad) with gentle mixing at 4 °C at 20 min intervals. A final 
addition of 180 mg Bio-Beads was incubated with the samples overnight. 
Proteoliposomes were first separated from the Bio-Beads by passage through 
empty spin columns (Bio-Rad), and subsequently pelleted at 120,000 x g for 60 
min. The proteoliposomes were resuspended with a thin needle in 150 μl of their 
supernatant after the rest of it was removed. 
Pyruvate transport assays  
The time course of pyruvate homo-exchange was measured at room temperature. 
The transport was initiated by diluting the proteoliposomes 200-fold into external 
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buffer, containing 50 μM [14C]-pyruvate (500,000 dpm, Perkin Elmer). The external 
buffers of different pH were i) 20 mM MES, pH 5.4, 50 mM NaCl ii) 20 mM MES, pH 
6.4, 50 mM NaCl iii) 20 mM Tris-HCl, pH 7.4, 50 mM NaCl iv) 20 mM Tris-HCl, pH 
8.0, 50 mM NaCl. The reaction (0–60 s) was terminated by rapid dilution into 8 
volumes of ice-cold internal buffer (20 mM Tris-HCl, pH 8.0, 50 mM NaCl or 20 mM 
Tris-HCl, pH 7.4, 50 mM NaCl, as indicated), followed by rapid filtration through 
cellulose nitrate 0.45 μm filters (Millipore) and washing with an additional 8 volumes 
of buffer. The filters were dissolved in Ultima Gold scintillation liquid (Perkin Elmer) 
and the radioactivity was counted with a Perkin Elmer Tri-Carb 2800 RT liquid 
scintilation counter. The initial rate measurements to determine kinetic parameters 
were taken after 5s of linear transport. Increasing concentrations of pyruvate were 
achieved by diluting the specific activity of [14C]-pyruvate with unlabelled pyruvate. 
For inhibition of pyruvate transport various concentrations (as indicated in the Figure 
legends) of UK5099, Zaprinast, lonidamine, 7ACC2, or the indicated TZDs were 
added to the liposomes simultaneously with 50 μM radioactive substrate. The data 
analysis was performed with non-linear regression fittings using GraphPad Prism 
7.0d ([Inhibitor] vs response, variable slope). The specific uptake rates were 
calculated based on the amount of protein used in reconstitutions, as determined by 
bicinchoninic acid assay. The biological repeats represent independent 
proteoliposome preparations using fresh protein from independent purifications. 
 
Peptide mass fingerprinting 
SDS polyacrylamide gel portions were subjected to in-gel proteolytic digestion with 
trypsin according to standard protocols. Extracted peptide mixtures were analysed 
with a 4800 MALDI-TOFTOF mass spectrometer (Applied Biosystems). Peptide 
fragmentation spectra were matched to the NCBI non-redundant DNA sequence 
database version 20120611 (18480950 sequences; 6336030745 residues) using the 
software package Mascot version 2.4 (Matrix Science www.matrixscience.com). 
Peptide ion scores greater than 58 points indicate identity or extensive homology 
(p<0.05). 
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Figure 1 - Purification and stability analysis of Mpc proteins. 
A Strategy for purification of the Mpc1/Mpc3 hetero-complex by nickel-affinity 
chromatography.  
 
B Expression of Mpc proteins in mitochondria assessed by SDS-PAGE and 
immunoblot analysis of crude mitochondrial preparations. The individual untagged 
Mpc1 (Mpc1), histidine-tagged Mpc1 (Mpc1his), histidine-tagged Mpc3 (Mpc3his) or 
the Mpc1/Mpc3 hetero-complex (Mpc1/Mpc3his) were detected with antibodies 
raised against Mpc1 (left panel) or Mpc3 (right panel) and are shown with dashed 
arrows. 
 
C Five micrograms of each affinity-purified Mpc protein were analysed by SDS-PAGE 
and the bands were visualised by Coomassie Blue stain. Peptide mass finger printing 
was used to identify the major protein bands (Table EV1).  
 
D The stability of the purified proteins was assessed via thermal denaturation by 
fluorescent CPM-adduct formation. The thermal denaturation profiles (left) were used 
to calculate the first derivative (right), which provides the apparent melting 
temperature, indicated with the same colour coding.  
 
E The stability of the same samples, as in panel (D), was assessed by NanoDSF. 
The changes in the 330 nm/350 nm ratio with temperature (left) were used to 
calculate the first derivative (right). Color coding is as in panel (D). 
 
Figure 2 - The Mpc proteins form dimeric complexes. 
A Nickel-affinity-purified Mpc1/Mpc3 hetero-complex used for SEC-MALLS analysis, 
showing a 1:1 stoichiometry of the protomers.  
 
B SEC-MALLS analysis of the hetero-complex. The light scattering trace for 
Mpc1/Mpc3 is shown as a black line. The masses of the protein-detergent-lipid 
complex (PDL, green), the detergent-lipid micelle (DL, blue) and the protein (P, red) 
are indicated. Protein fractions across the peak were assessed by SDS-PAGE and 
visualised by Coomassie Blue staining (B, inset).  
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C Nickel-affinity-purified Mpc3 protein used for SEC-MALLS analysis.  
 
D SEC-MALLS analysis of Mpc3, colour designation as in (B). The protein fractions 
across the peak (D, inset) were assessed as in (B).  
 
Data information: Data in (B and D) represent a characteristic experiment repeated 
independently five times for Mpc1/Mpc3 and three times for Mpc3. All biological 
repeats are summarised in Table EV2. 
 
Figure 3 - The Mpc1/Mpc3 hetero-complex transports pyruvate. 
A Time course of pyruvate homo-exchange by the Mpc1/Mpc3 hetero-complex in 
liposomes (n=8) in comparison to empty liposomes (n=6) at a ΔpH of 1.6.  
 
B Kinetic analysis of pyruvate homo-exchange at ΔpH of 1.6 (n=3). The hetero-
complex was assayed for initial rates of uptake in the concentration range of 25-600 
μM. The calculated KΜ was 299 μΜ in this experiment and 318 and 409 μΜ in two 
additional biological repeats. 
 
C Time course of pyruvate homo-exchange by the Mpc1/Mpc3 hetero-complex in 
physiological pH (n=4) compared to empty liposomes (n=4).  
 
D In the absence of a ΔpH, the time course of pyruvate homo-exchange was similar 
for the Mpc1/Mpc3 proteoliposomes and the empty liposomes (n=4).  
 
E Inhibition of [14C]-pyruvate homo-exchange by UK5099 (1–100 μM), Zaprinast (1–
1000 μM), lonidamine (10–10000 μM) and 7ACC2 (5–500 μM). Data points represent 
the mean of three technical replicates of a typical experiment. The IC50 
measurements have also been independently replicated, three times for UK5099 
Zaprinast and 7ACC2 (average IC50 9 ± 7 μM, 18 ± 8 μM and 27 ± 13 μM, 
respectively) and two times for lonidamine (average IC50, 118 ± 24 μM). 
 
F [14C]-pyruvate homo-exchange inhibition by the TZDs, pioglitazone and 
rosiglitazone (n=6).  
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Data information: Data have been independently replicated: (A) four biological 
repeats, (B) three biological repeats, (C, D) 2 biological repeats (E, F) three biological 
repeats for UK5099, Zaprinast, 7ACC2 and two biological repeats for lonidamine and 
the TZDs. The error bars represent the standard error of the mean in (A) and the 
standard deviation in (C, D and F). 
 
Figure 4 - Mpc1 or Mpc3 alone are not functional. 
A Time course of pyruvate homo-exchange in proteoliposomes at a ΔpH of 1.6 was 
compared for Mpc3 (n=4), the Mpc1/Mpc3 hetero-complex (n=6) and empty 
liposomes (n=4). 
 
B Time course of pyruvate homo-exchange at a ΔpH of 1.6 was compared for Mpc1 
(n=4), Mpc1/Mpc3 hetero-complex (n=4) and empty liposomes (n=4).  
 
C Thermostability analysis via cpm. In detergent solution, Zaprinast (250 μM) 
increased the thermostability of the Mpc1/Mpc3 hetero-complex (black lines) (n=3) 
but not of Mpc3 (blue lines) (n=3).  
 
D Thermostability analysis via nanoDSF. In detergent solution, Zaprinast (250 μM) 
increased the thermostability of the Mpc1/Mpc3 hetero-complex (black lines) (n=3) 
but not of Mpc1 (orange lines) (n=3).  
 
Data information: Data have been independently replicated in two biological repeats. 











Expanded View Figure Legends 
Figure EV1 - Topology of yeast Mpc1, Mpc2 and Mpc3.  
The alignment was generated by Clustal Omega and by manual curation (Sievers et 
al., 2011). The aligned residues are coloured by the ZAPPO colour scheme in which 
aliphatic, polar, aromatic, positively charged, negatively charged, Pro/Gly and Cys, 
are coloured pink, green, orange, blue, red, magenta and yellow, respectively. The 
asterisks indicate identical residues and the colon conserved substitutions. Also 
indicated are putative transmembrane helices, loop regions and the N-terminal 
amphipathic helix. The secondary structure elements were assigned based on 
PSIPRED (Buchan et al., 2013), MEMSAT3 (Jones et al., 1994) and conservation 
analysis. 
 
Figure EV2 - The Mpc1/Mpc3 hetero-complex purified in different detergents. 
The Mpc1/Mpc13p hetero-complex was purified in n-dodecyl β-D-maltoside (DDM), 
decyl maltose neopentyl glycol (DMNG) or Triton X-100. The solubilisation of 
mitochondria was performed as under Materials and Methods but in buffer containing 
2 % (w/v) DDM or DMNG or 1% Triton X-100. For affinity purification, the Nickel 
Sepharose columns were washed with wash buffers containing 0.1 % (w/v) DDM, 
DMNG or Triton X-100 supplemented with 0.1 mg/ml tetraoleoyl cardiolipin 
(TOCL). The samples are the solubilisate of mitochondria (Sol), proteins remaining 
on the resin after Factor Xa cleavage (B) and flow-through from the resin (FT). 
Asterisks indicate the Mpc1 and Mpc3 proteins. 
 
Figure EV3 - Size-exclusion chromatography.  
A Size-exclusion chromatography of 500 μg nickel-affinity purified Mpc1/Mpc3 
hetero-complex. In the A280 profiles, the Mpc1/Mpc3 hetero-complex was present in a 
symmetrical peak.  
 
B Size-exclusion chromatography of 150 μg nickel-affinity purified Mpc3. Mpc3 
produced a peak similar to that of Mpc1/Mpc3.  
 
Data information: Insets in (A and B) show peak fractions collected and analysed by 
SDS-PAGE and visualised by Coomassie Blue stain. 
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Figure EV4 - Purification and stability analysis of the hetero-complex 
Mpc1/Mpc2. 
A The individual histidine-tagged Mpc1 (Mpc1his), histidine-tagged Mpc2 (Mpc2his) 
or the Mpc1/Mpc2 hetero-complex (Mpc1/Mpc2his) were expressed in the triple mpc 
knock-out strain SHY15 and detected with antibodies raised against Mpc1 (left) or 
against the histidine tag (right).  
 
B SDS-PAGE analysis of purified Mpc1, Mpc2 and Mpc1/Mpc2 proteins, visualised 
with Coomassie Blue stain. As the yield of the purified Mpc2 was very low, the 
protein was not visible with Coomassie Blue stain, but was identified on the gel by 
peptide mass finger printing (Table EV1).  
 
C The stability of the purified Mpc1/Mpc2 or Mpc2 was assessed via the CPM 
method. Thermal denaturation profiles (upper panel) were used to calculate the first 
derivative of the data (lower panel). The number is the apparent melting temperature 
for the Mpc1/Mpc2 hetero-complex. 
 
D Time course of pyruvate homo-exchange by the Mpc1/Mpc2 hetero-complex in 
liposomes in comparison to empty liposomes at a ΔpH of 1.6 (n=2).  
 
 
Figure EV5 – Effect of pH on pyruvate homo-exchange in Mpc1/Mpc3-
containing proteoliposomes compared to diffusion of pyruvate into empty 
liposomes.  
Pyruvate homo-exchange of Mpc1/Mpc3 proteoliposomes or empty liposomes was 
tested in three conditions. 
A In the absence of a ΔpH, using an internal buffer pH of 7.4 and external buffer pH 
of 7.4 (n=2).  
 
B At a ΔpH of 1.0, using an internal buffer pH of 7.4 and external buffer pH of 6.4 
(n=4).  
 







Table 1 - Stoichiometry analysis of the Mpc1/Mpc3 complex. 
 










1 0 1.628 15 32.92 17.92 
0 1 1.868 17.12 28.69 11.57 
Homo-dimer 
2 0 1.633 29.97 32.9 2.93 
0 2 1.869 34.21 28.68 -5.53 
Hetero-dimer 
1 1 1.757 32.1 30.83 -1.27 
Homo-trimer 
3 0 1.629 44.95 32.9 -12.05 
0 3 1.869 51.31 29.6 -21.71 
Hetero-trimer 
2 1 1.716 47.07 31.21 -15.86 
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MPC1 1 77MSQ P VQ RA A A RS F LQ K Y I NK E T L K Y I F T T HF WG P V S NF G I P I A A I Y D L K K DP T L I SG PMT F A L V T Y SG V F MK Y A L S V
MPC2 1 71- - - - MS T S S V RF A F RRF WQ S E T G - - P K T V HF WA P T L KWG L V F AG F S DMK RP V E K I SG AQ N L S L L S T A L I WT RWS F V I
MPC3 1 71- - - - MS A S A F NF A F RRF WNS E T G - - P K T V HF WA P T L KWG L V F AG L ND I K RP V E K V SG AQ N L S L L A T A L I WT RWS F V I
transmembrane helix 2L1-2amphipathic helix transmembrane helix 1
** *** ** * * *** **
MPC2 72 129K P RN I L L A S V NS F L C L T AG YQ LG R I A NY R I RNG DS I SQ L CS Y I L SG A DE S K K E I T T G R
transmembrane helix 3L2-3
MPC1 78 130S P K NY L L F G CH L I NE T AQ L AQG Y RF L K Y T Y F T T DE E K K A L DK EWK E K E K T G KQ - - - - -
MPC3 72 146K P K NY L L A S V NF F LG CT AG Y H L T R I A NF R I RNG DS F KQ V I HY I I KG E T P A A V A A KQ T A S T SMNKG V I G T NP P I T H
* * * * **
DDM DMNG Triton X-100
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